Venki describes the importance of Max’s work in laying the foundations of molecular and structural biology and in the origin of the LMB. More…
LMB In The News
Cambridge Independent features the future of LMB’s Nobel-winning technology
Chris Russo, Katerina Naydenova and Greg McMullan discuss the latest developments in the field of cryo-EM with Paul Brackley of the Cambridge Independent. “Based on this research, several companies and research groups are now working to make this technology widely available, as part of a simple cheap microscope that any biology lab will be able […]
Nature’s 150th anniversary issue celebrates Georges Köhler, Cesar Milstein and Greg Winter’s pioneering role in the rise of monoclonal antibodies
This Nature opinion piece recounts the dramatic impact of the pivotal 1975 paper by Köhler–Milstein on biomedical and, specifically, immunological research, which was propelled by scientific developments that occurred around the time the paper appeared. It also chronicles the research on monoclonal antibodies over the years all the way to Greg Winter’s research, which features […]
Greg Winter and the promise of antibody-based therapies
In conversation with the FEBS Journal, Greg discusses his early motivations, monoclonal antibody therapy research, life after the Nobel prize, and balancing entrepreneurship with science. He also lets in on a secret childhood fantasy, “As a boy I fancied being the captain of tramp steamer plying the South Pacific…”. More…
Madeline Lancaster explains brain organoids to The Times
Simon Crompton of The Times interviews Madeline about her early experience when growing mini brains in the lab and the journey towards insights into human brain development and what fundamentally sets us apart from animals (story behind paywall). More…
Benjamin Falcon discusses his research in Neuronet’s first newsletter
LMB’s newly recruited Group Leader weighs in on various aspects of Alzheimer’s Disease, from the clinical implications of deciphering Tau filaments in brains of people suffering from neurodegenerative diseases, to designing precise drugs. More…